Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Type of study
Language
Publication year range
1.
Br J Dermatol ; 176(1): 209-211, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27088428

ABSTRACT

Dermatomyositis (DM) is commonly associated with scalp pruritus that can be severe. In addition, significant crawling and burning sensations have been reported in these cases. The aetiology of these scalp sensations in the context of DM is not fully understood. We report a 42-year-old female with treatment-resistant DM and structural changes in scalp epidermal and dermal nerve fibres. The patient presented with characteristic skin manifestations (Gottron's papules and poikiloderma), severely pruritic scalp, intermittent muscle weakness on neurological exam with electrodiagnostically confirmed myositis, and joint pain. Structural changes in scalp epidermal and dermal nerve fibres were discovered in a skin biopsy, suggesting that small-fibre neuropathy associated with scalp pruritus may be a manifestation of the DM syndrome. Further clinical experience combined with selective skin biopsy in patients with DM and symptomatic scalp will help determine the frequency of coexistent small nerve fibre involvement. Based on our limited findings, we suggest that pruritus in DM may be associated with abnormal epidermal and dermal nerve fibre structure.


Subject(s)
Dermatomyositis/complications , Pruritus/etiology , Scalp Dermatoses/complications , Small Fiber Neuropathy/etiology , Adult , Dermatomyositis/diagnostic imaging , Female , Humans , Microscopy, Confocal , Muscle Weakness/etiology , Scalp Dermatoses/diagnostic imaging , Small Fiber Neuropathy/diagnostic imaging
2.
J Clin Pharm Ther ; 38(2): 175-6, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23210935

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Posterior reversible encephalopathy syndrome (PRES) can be the result of acute hypertension, eclampsia, renal failure and the use of immunosuppressive or cytotoxic agents. We report a case of PRES as a result of the use of pazopanib, a vascular endothelial growth factor inhibitor used for renal cell carcinoma (RCC). CASE SUMMARY: A 76-year-old man treated with RCC develops PRES shortly after the initiation of pazopanib. WHAT IS NEW AND CONCLUSION: There are no known reports of the association between PRES and pazopanib. We postulate that pazopanib can disrupt the normal endothelial function of the brain leading to the development of PRES.


Subject(s)
Carcinoma, Renal Cell/drug therapy , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Kidney Neoplasms/drug therapy , Posterior Leukoencephalopathy Syndrome/chemically induced , Pyrimidines/adverse effects , Pyrimidines/therapeutic use , Sulfonamides/adverse effects , Sulfonamides/therapeutic use , Aged , Humans , Indazoles , Male , Vascular Endothelial Growth Factor A/antagonists & inhibitors
SELECTION OF CITATIONS
SEARCH DETAIL